Cantor Fitzgerald initiated coverage on Ocugen with a new price target
$OCGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cantor Fitzgerald initiated coverage of Ocugen with a rating of Overweight and set a new price target of $4.50